Pacira’s (PCRX) first-quarter earnings are expected to decline

Pacira (PCRX) is expected to report a year-over-year earnings decline on lower revenues in its report for the quarter ended March 2023. This widely known consensus outlook paints a good picture of the company’s earnings picture, but how actual results compare to these estimates is a significant factor that could impact the near-term share price.

Shares could rise if these key numbers beat expectations in the upcoming earnings report. On the other hand, if they miss, the stock could fall.

While the sustainability of the immediate price movement and future earnings expectations will largely depend on management’s discussion of business conditions during the earnings call, it is worth limiting the likelihood of a positive EPS surprise.

Zacks Consensus Estimate

The specialty drug maker is expected to post quarterly earnings per share of $0.60 per share in its upcoming report, representing a year-over-year change of -6.3%.

Revenue is expected to be $157.02 million, down 0.6% from the year-ago quarter.

Estimate the trend of change

The consensus EPS estimate for this quarter has been revised 1.07% down to the current level over the last 30 days. This broadly reflects how analysts covering the data have collectively re-evaluated their initial estimates during this period.

Investors should note that the direction of each analyst’s estimate revisions will not always be reflected in the aggregate change.

Whisper about earnings

Revisions to estimates prior to a company’s earnings release provide an indication of business conditions in the period in which the earnings are expected to be released. This insight is at the heart of our proprietary surprise prediction model, the Zacks Earnings ESP.

The Zacks Earnings ESP compares the Most Accurate Estimates to the Zacks Consensus Estimates for the quarter; The Most Accurate Estimate is a newer revision of the Zacks Consensus EPS estimate. The idea is that analysts reviewing their estimates just before an earnings release have the latest information, which could potentially be more accurate than what they and other consensus participants had previously predicted.

Thus, a positive or negative ESP reading theoretically indicates the likely deviation of actual earnings from consensus estimates. However, the predictive power of the model is only significant for positive ESP readings.

A positive Earnings ESP is a strong predictor of an earnings beat, especially when paired with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks in this combination deliver a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of its Earnings ESP.

Please note that a negative earnings ESP reading does not mean a loss of earnings. Our research shows that it is difficult to predict earnings growth with any degree of confidence for stocks with negative ESP readings and/or a Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How have the numbers changed for Pacira?

For Pacira, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company’s earnings prospects. This resulted in an earnings ESP of -5%.

On the other hand, the stock currently sports a Zacks Rank of #4.

So this combination makes it difficult to confidently predict that Pacira will beat the consensus EPS estimate.

Does the history of surprising results have any clue?

When calculating estimates of a company’s future earnings, analysts often consider how well the company has been able to match previous estimates. So it’s worth taking a look at the history of surprises to assess its impact on the upcoming issue.

In the most recent quarter, Pacira was expected to post earnings of $0.80 per share when it actually produced earnings of $0.80, which was no surprise.

The company has failed to beat consensus EPS estimates in each of the last four quarters.

Bottom line

Improving or lacking earnings may not be the only basis for a stock’s value rising or falling. Many stocks lose value despite good earnings because of other factors that disappoint investors. Similarly, unforeseen catalysts help many stocks gain despite losing profits.

That said, betting on stocks that are expected to exceed earnings expectations increases your chances of success. Therefore, it is worth checking the company’s Earnings Rank and Zacks Rank before their quarterly release. Use our Earnings ESP filter to find the best stocks to buy or sell before they report.

Pacira doesn’t seem like a compelling candidate to beat earnings. However, investors should also pay attention to other factors if they want to bet on or stay away from these stocks ahead of an earnings release.

Expected results of an industry player

Stocks in the Zacks Medical – Drugs industry are soon expected to report a loss of $0.09 per share for Rigel Pharmaceuticals (RIGL) for the quarter ended March 2023. This estimate indicates a year-over-year change of +43.8%. Revenue for the quarter is expected to be $24.29 million, up 45.1% from the same quarter last year.

Over the last 30 days, the consensus EPS estimate for Rigel has been revised 3.1% down to the current level. Nevertheless, the company currently has an Earnings ESP of 0.00%, which reflects the equal most accurate estimate.

This earnings ESP, combined with a Zacks Rank #3 (Hold), makes it difficult to firmly predict that Rigel will surpass the consensus EPS estimate. The company has topped consensus EPS estimates three times over the last four quarters.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Want the latest recommendations from Zacks Investment Research? Today you can download the top 7 stocks for the next 30 days. Click to get this free report

Pacira BioSciences, Inc. (PCRX): Free Stock Analysis Report

Rigel Pharmaceuticals, Inc. (RIGL): Free Inventory Analysis Report

To read this article on click here.

Zacks Investment Research